Skip to main content

Published locations for CML-CP: Addition of PegIFN- to dasatinib well tolerated and effective in long term treatment

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. CML-CP: Addition of PegIFN- to dasatinib well tolerated and effective in long term treatment

User login

  • Reset your password
  • /content/cml-cp-addition-pegifn-dasatinib-well-tolerated-and-effective-long-term-treatment
  • /hematology-oncology/article/246642/cml/cml-cp-addition-pegifn-dasatinib-well-tolerated-and-effective